Prevalence of Adult Type 2 Diabetes Mellitus and Related Complications in Alberta, Canada: A Retrospective Observational Study using Administrative Data.
Administrative Data
Cardiovascular medicine
Diabetes
Epidemiology
Morbidity
Nephrology
Journal
Canadian journal of diabetes
ISSN: 2352-3840
Titre abrégé: Can J Diabetes
Pays: Canada
ID NLM: 101148810
Informations de publication
Date de publication:
20 Dec 2023
20 Dec 2023
Historique:
received:
24
04
2023
revised:
28
11
2023
accepted:
14
12
2023
medline:
23
12
2023
pubmed:
23
12
2023
entrez:
22
12
2023
Statut:
aheadofprint
Résumé
Type 2 diabetes mellitus (T2DM) is a prevalent chronic disease and a leading cause of morbidity/mortality in Canada. We evaluated the burden of T2DM in Alberta, Canada by estimating the five-year period prevalence of T2DM and rates of comorbidities and complications/conditions after T2DM. We conducted a population-based retrospective study linking administrative health databases. T2DM patients (≥18 years) were identified between 2008/09-2018/19 using a published algorithm, with follow-up data to March 2020. Five-year period prevalence was estimated between 2014/15-2018/19. Patients with newly-identified T2DM, ascertained between 2010/11-2017/18 with a lookback period between 2008/09-2009/10 and a minimum one-year of follow-up data, were evaluated for subsequent cardiovascular, diabetic, renal, and other complication/condition frequencies (%) and rates (/100 person-years). Complications/conditions were stratified by atherosclerotic cardiovascular disease (ASCVD) status at index and age. The five-year period prevalence of T2DM was 11,051 per 100,000 persons, with the highest prevalence in males aged 65-<75 years. There were 195,102 patients included in the cohort (mean age of 56.7±14.7 years). The most reported complications/conditions (rates /100 person-years) were acute infection (23.10, 95% confidence interval [CI]: 23.00-23.30), hypertension (17.30, 95% CI: 16.80-17.70), and dyslipidemia (12.20, 95% CI: 11.90-12.40)). Those who experienced an ASCVD event/procedure and those aged ≥75 years, had higher rates of complications/conditions. Our study found over half of patients experienced hypertension or infection after T2DM. Further, those with ASCVD had higher rates of complications/conditions. Strategies to mitigate complications/conditions after T2DM are required to reduce the burden of T2DM on patients and healthcare systems.
Sections du résumé
BACKGROUND
BACKGROUND
Type 2 diabetes mellitus (T2DM) is a prevalent chronic disease and a leading cause of morbidity/mortality in Canada. We evaluated the burden of T2DM in Alberta, Canada by estimating the five-year period prevalence of T2DM and rates of comorbidities and complications/conditions after T2DM.
METHODS
METHODS
We conducted a population-based retrospective study linking administrative health databases. T2DM patients (≥18 years) were identified between 2008/09-2018/19 using a published algorithm, with follow-up data to March 2020. Five-year period prevalence was estimated between 2014/15-2018/19. Patients with newly-identified T2DM, ascertained between 2010/11-2017/18 with a lookback period between 2008/09-2009/10 and a minimum one-year of follow-up data, were evaluated for subsequent cardiovascular, diabetic, renal, and other complication/condition frequencies (%) and rates (/100 person-years). Complications/conditions were stratified by atherosclerotic cardiovascular disease (ASCVD) status at index and age.
RESULTS
RESULTS
The five-year period prevalence of T2DM was 11,051 per 100,000 persons, with the highest prevalence in males aged 65-<75 years. There were 195,102 patients included in the cohort (mean age of 56.7±14.7 years). The most reported complications/conditions (rates /100 person-years) were acute infection (23.10, 95% confidence interval [CI]: 23.00-23.30), hypertension (17.30, 95% CI: 16.80-17.70), and dyslipidemia (12.20, 95% CI: 11.90-12.40)). Those who experienced an ASCVD event/procedure and those aged ≥75 years, had higher rates of complications/conditions.
CONCLUSION
CONCLUSIONS
Our study found over half of patients experienced hypertension or infection after T2DM. Further, those with ASCVD had higher rates of complications/conditions. Strategies to mitigate complications/conditions after T2DM are required to reduce the burden of T2DM on patients and healthcare systems.
Identifiants
pubmed: 38135113
pii: S1499-2671(23)00723-2
doi: 10.1016/j.jcjd.2023.12.004
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.